Peter Lawson
Stock Analyst at Barclays
(1.23)
# 3,522
Out of 4,884 analysts
105
Total ratings
35.63%
Success rate
-15.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.46 | +105.48% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.12 | +78.57% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.25 | +84.00% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $4.39 | +127.79% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $1.75 | +128.57% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $8.42 | -28.74% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $5.86 | +87.71% | 1 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $32 → $16 | $7.95 | +101.26% | 8 | May 2, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Overweight | $40 → $15 | $7.43 | +101.88% | 2 | May 1, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $29 → $14 | $8.47 | +65.29% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.66 | +80.72% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.51 | +98.68% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.43 | +179.72% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $29 | $46.15 | -37.16% | 5 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $37.87 | +58.44% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.63 | +368.32% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $9.00 | +266.67% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $33.02 | +99.88% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $105 | $128.35 | -18.19% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $12.73 | +143.52% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $9.40 | +80.85% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $5.70 | +128.07% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.79 | +529.80% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $2.50 | +40.00% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $100.80 | +262.10% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $36.07 | +27.53% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $24.76 | +1,717.45% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.57 | +1,650.97% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $52.17 | -13.74% | 2 | Jan 23, 2018 |
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.46
Upside: +105.48%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.12
Upside: +78.57%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.25
Upside: +84.00%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $4.39
Upside: +127.79%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.75
Upside: +128.57%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $8.42
Upside: -28.74%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $5.86
Upside: +87.71%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $7.95
Upside: +101.26%
Bicycle Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $7.43
Upside: +101.88%
Arcus Biosciences
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $8.47
Upside: +65.29%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.66
Upside: +80.72%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.51
Upside: +98.68%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.43
Upside: +179.72%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $25 → $29
Current: $46.15
Upside: -37.16%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $37.87
Upside: +58.44%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.63
Upside: +368.32%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $9.00
Upside: +266.67%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $33.02
Upside: +99.88%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $128.35
Upside: -18.19%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $12.73
Upside: +143.52%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $9.40
Upside: +80.85%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $5.70
Upside: +128.07%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.79
Upside: +529.80%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.50
Upside: +40.00%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $100.80
Upside: +262.10%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $36.07
Upside: +27.53%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $24.76
Upside: +1,717.45%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.57
Upside: +1,650.97%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $52.17
Upside: -13.74%